ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. XOMA Royalty's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -1.07%.
As of today (2026-06-30), XOMA Royalty's WACC % is 7.83%. XOMA Royalty's ROIC % is 3.03% (calculated using TTM income statement data).
XOMA Royalty earns returns that do not match up to its cost of capital. It will destroy value as it grows.
XOMA Royalty (NAS:XOMA) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, XOMA Royalty's WACC % is 7.83%. XOMA Royalty's ROIC % is 3.03% (calculated using TTM income statement data).
XOMA Royalty earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
XOMA Royalty ROIC % Related Terms
XOMA Royalty ROIC % Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XOMA Royalty's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty ROIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's ROIC % distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's ROIC % falls into.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA Royalty (XOMA) has a ROIC % of -1.07% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on XOMA Royalty and its competitors.
Is XOMA Royalty's ROIC % too high?
XOMA Royalty's current ROIC % is -1.07%. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's ROIC % compare to CLYM and CTMX?
XOMA Royalty's ROIC % of -1.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current ROIC % is -1.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.85, compared to a current price of $42.15 — trading 123.6% above its estimated fair value. The current ROIC % is -1.07%. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current ROIC % is -1.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $42.15 is trading 123.6% above its estimated GF Value™ of $18.85.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
ROIC %: -1.07%
GF Value™: $18.85 vs. price of $42.15 (123.6% above fair value)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score
Get the complete analysis for XOMA
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
